Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Primary Immune Thrombocytopenia

NCT03102593 is registered in ClinicalTrials.gov with argenx as lead sponsor.

NCT NCT03102593
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03102593 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Primary Immune Thrombocytopenia
Lead sponsor
argenx
Phase
Phase 2
Overall status
Completed
Start date
March 13, 2017
Completion date
April 9, 2019
Enrollment
38 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

primary immune thrombocytopenia